Crofelemer

Drug Profile

Crofelemer

Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002; Virend

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Glenmark Pharmaceuticals Ltd; Napo Pharmaceuticals; Shaman Pharmaceuticals
  • Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Phytotherapies
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diarrhoea
  • Phase II Irritable bowel syndrome
  • Preclinical Short bowel syndrome
  • Discontinued Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 07 Aug 2017 Preclinical trials in Short bowel syndrome in USA (PO) before August 2017
  • 07 Aug 2017 Crofelemer receives Orphan Drug status for Short bowel syndrome in USA
  • 25 Jul 2017 Additional efficacy data from the phase III ADVENT trial in Diarrhoea released by Napo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top